Investigators
Lauren B. Bruckner, M.D., Ph.D.
-
Infections in the immunocompromised host
-
Mechanisms of acute lung injury following hematopoietic stem cell transplantation
Lisa R. Hackney, M.D.
-
Principle Investigator for Children's Oncology Group Program
Paul D. Kingsley, Ph.D.
David N. Korones, M.D
-
Clinical trials of new agents for children and adults with newly diagnosed and recurrent brain tumors
-
Palliative and end-of-life care for children
Kathleen E. McGrath, Ph.D.
Our research focuses on the ontogeny of the mammalian hematopoietic system. Formation of blood is a critical early event for mammalian embryos, initially occurring in the extraembryonic yolk sac of the gastrulating embryo, then migrating to the fetal liver, and finally homing to the bone marrow at the end of gestation. Our studies utilize the mouse embryo, adult bone marrow, and embryonic stem cells as primary model systems to investigate the initial appearance and differentiation of hematopoietic progenitors and precursors as well as their selective response to radiation damage. For further information please see the Palis Lab
Craig A. Mullen, M.D., Ph.D.
-
Identification of immunological mechanisms that can be used to design therapies to prevent the recurrence of leukemia in pediatric patients following allogeneic HCS transplant
-
Newborn genetic screening for hemoglobinopathies
James Palis, M.D.
-
Cellular and molecular events underlying the initiation of hematopoiesis in the mammalian embryo
-
Mechanisms regulating terminal differentiation of fetal and adult erythriod precursors
-
Response of the erythroid lineage to radiation
Olle Jane Z. Sahler, M.D.
-
Chronic and terminal illness in children
-
Sibling adaptation to childhood cancer
-
Problem-solving skills training
-
Cognitive remediation in cancer survivors
-
The use of complementary medicine in allopathic practice
-
Child and adolescent obesity
-
Palliative and end-of-life care for children
Jessica Shand, M.D., M.H.S.
-
Mechanisms of immune escape in lymphoblastic leukemia that can be targeted to improve the potency of adoptive immunotherapy
-
Biology of native and adoptive CD8+ T cell responses to lymphoblastic leukemia
-
Augmentation of immunogenic cell death in lymphoblastic leukemia
-
Using the above observations to shift the timing of adoptive immunotherapy for lymphblastic leukemia from the relapsed/refractory setting to the minimal residual disease setting